Trial reportAntimicrobial agents and chemotherapy2009
Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.
Trial report in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Duration of intravenous antibiotic therapy in people with cystic fibrosis.The Cochrane database of systematic reviews · 2019Pooled it
- Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Pooled it
- Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.The Cochrane database of systematic reviews · 2015Pooled it
- An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations.Open forum infectious diseases · 2026Trial
- Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.Antimicrobial agents and chemotherapy · 2010Trial
- Modeling of pharmacokinetic/pharmacodynamic parameters in regular intermittent intravenous infusion and translational application of the models in personalized antibiotics dosing.Journal of translational medicine · 2025Article
- Optimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2023Review
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.Scientific reports · 2022Article
- A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity.Paediatric drugs · 2021Article
- Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clinical pharmacokinetics · 2021Review
- Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?Antibiotics (Basel, Switzerland) · 2020Review
- Acute Pulmonary Exacerbations in Cystic Fibrosis.Seminars in respiratory and critical care medicine · 2019Review
- Article
- Article
- Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Science advances · 2017Article
- Duration of intravenous antibiotic therapy in people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present multicenter, randomized crossover study compared the safety and efficacy of continuous infusion with those of short infusions of ceftazidime in patients with cystic fibrosis. Patients with chronic Pseudomonas aeruginosa colonization received two successive courses of intravenous tobramycin and ceftazidime (200 mg/kg of body weight/day) for pulmonary exacerbation administered as thrice-daily short infusions or as a continuous infusion. The primary endpoint was the variation in the forced expiratory volume in 1 s (FEV1) during the course of antibiotic treatment. Sixty-nine of the 70 patients enrolled in the study received at least one course of antibiotic treatment. The improvement in FEV1 at the end of therapy was not statistically different between the two treatment procedures (+7.6% after continuous infusion and +5.5% after short infusions) but was better after continuous ceftazidime treatment in patients harboring resistant isolates (P < 0.05). The interval between the course of antibiotic treatments was longer after the continuous infusion than after the short infusion of ceftazidime (P = 0.04). The mean serum ceftazidime concentration during the continuous infusion was 56.2 +/- 23.2 microg/ml; the mean peak and trough concentrations during the short infusions were 216.3 +/- 71.5 and 12.1 +/- 8.7 microg/ml, respectively. The susceptibility profiles of the P. aeruginosa isolates remained unchanged and were similar for both regimens. Quality-of-life scores were similar whatever the treatment procedure, but 82% of the patients preferred the continuous-infusion regimen. Adverse events were not significantly different between the two regimens. In conclusion, the continuous infusion of ceftazidime did not increase its toxicity and appeared to be as efficient as short infusions in patients with cystic fibrosis as a whole, but it gave better results in patients harboring resistant isolates of P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.